Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

Completed · Phase 2

Conditions studied: Cancer

In brief

MEK113583 is a Phase II open-label, multi-site study to investigate the objective response rate, safety, and pharmacokinetics of GSK1120212 in subjects with BRAF mutation-positive melanoma who were previously treated with or without a BRAF inhibitor. GSK1120212 is a potent and highly selective inhibitor of MEK activation and kinase activity.

Key facts

Study ID

NCT01037127

Run by

GlaxoSmithKline

People needed

97

Starts

2009-11-01

Expected to finish

2013-01-01

Last updated by the study team

2014-03-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Metastatic cutaneous melanoma that was previously treated with: (Cohort A) a BRAF inhibitor either with or without other prior therapy. (Cohort B) at least 1 prior chemotherapy or immunotherapy, without treatment with a BRAF inhibitor.
• Documented positive BRAF mutation (V600E, V600K, or V600D).
• Subjects must provide archived tumor tissue or undergo fresh tumor biopsy prior to enrollment.
• The subject must have a radiographically measurable tumor.
• The subject is able to carry out daily life activities without significant difficulty (ECOG performance status score of 0 or 1).
• Able to swallow and retain oral medication.
• Sexually active subjects must use acceptable methods of contraception during the course of the study.
• Adequate organ system function and blood cell counts.

You may not qualify if…

• The subject has had major surgery or received certain types of cancer therapy within 21 days before starting the study.
• Previous treatment with a MEK inhibitor.
• Current use of a prohibited medication listed in the protocol.
• Uncontrolled glaucoma.
• Brain metastasis, unless previously treated with surgery or stereotactic radiosurgery, and the disease has been stable for at least 2 months prior to enrollment.
• Current severe or uncontrolled systemic disease.
• History of clinically significant heart, lung, or eye/vision problems.
• Significant unresolved side effects from previous anti-cancer therapy.
• The subject is pregnant or breastfeeding.

Where it is running

• GSK Investigational Site — Los Angeles, California, United States
• GSK Investigational Site — Aurora, Colorado, United States
• GSK Investigational Site — New York, New York, United States
• GSK Investigational Site — Philadelphia, Pennsylvania, United States
• GSK Investigational Site — Nashville, Tennessee, United States
• GSK Investigational Site — Nashville, Tennessee, United States
• GSK Investigational Site — Houston, Texas, United States
• GSK Investigational Site — Westmead, New South Wales, Australia
• GSK Investigational Site — East Melbourne, Victoria, Australia
• GSK Investigational Site — Nedlands, Western Australia, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.